Clinical trial NCT06232226: Attention Deficit Hyperactivity Disorder
Official title: Addictions and Attention Deficit Disorder With or Without Hyperactivity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Attention Deficit Hyperactivity Disorder
Behavior Hyperactive
Behavior Disorders
Keywords: Attention Deficit Disorder with Hyperactivity
Addictive disorders
Neuropsychology
Methylphenidate
Atomoxetine
Functional impairment
Symptoms
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2024-01-30
Enrollment: 60
Sex: ALL
Minimum age (years): 15
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Cohort
Primary purpose: OTHER

Brief summary: The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.

Detailed description: Information on the study and diagnosis of ADHD will be carried out during a medical evaluation consultation, as part of routine care.

The two research visits (inclusion and at 12 months) will be added by the research and will each include:

* A structured clinical interview with a research professional (traceability of oral consent, administration of structured interviews, collection of self-questionnaires, collection of care from the medical record)
* A neuropsychological assessment with a neuropsychologist

Eligibility criteria: Inclusion Criteria :

* Patients aged over 15 years and 3 months
* For whom a diagnosis of ADHD has been confirmed less than 6 weeks ago
* For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed
* Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)
* For patients who can actually benefit from MPH: who have not yet started taking MPH
* Social security affiliates

Exclusion Criteria :

* Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible
* Presenting difficulties in reading or writing the French language making data collection impossible
* Unable to commit to being available for the 2 visits planned as part of the cohort
* Under guardianship or legal protection

Primary outcomes:
measure: Functional impairment
timeFrame: Inclusion and 12-month follow-up
Secondary outcomes:
measure: Type and severity of ADHD
timeFrame: Inclusion
measure: Symptoms of ADHD
timeFrame: Inclusion and 12-month follow-up
measure: Addictive disorders - substance use disorders (including tobacco, alcohol and other substances)
timeFrame: Inclusion and 12-month follow-up
measure: Addictive disorders - gambling disorder
timeFrame: Inclusion and 12-month follow-up
measure: Addictive disorders - sex addiction
timeFrame: Inclusion and 12-month follow-up
measure: Addictive disorders - gambling disorder
timeFrame: Inclusion and 12-month follow-up
measure: Addictive disorders - eating addiction
timeFrame: Inclusion and 12-month follow-up
measure: Psychiatric disorders
timeFrame: Inclusion and 12-month follow-up
measure: Neuropsychological profile - selective attention
timeFrame: Inclusion and 12-month follow-up
measure: Neuropsychological profile - short-term and working memory
timeFrame: Inclusion and 12-month follow-up
measure: Neuropsychological profile - inhibition
timeFrame: Inclusion and 12-month follow-up
measure: Neuropsychological profile - spontaneous flexibility
timeFrame: Inclusion and 12-month follow-up
measure: Neuropsychological profile - planning
timeFrame: Inclusion and 12-month follow-up
measure: Psychopathological profile - impulsivity
timeFrame: Inclusion and 12-month follow-up
measure: Psychopathological profile - emotional dysregulation
timeFrame: Inclusion and 12-month follow-up
measure: Psychopathological profile - sensorial profile
timeFrame: Inclusion and 12-month follow-up
measure: Psychopathological profile - self-esteem
timeFrame: Inclusion and 12-month follow-up
measure: Quality of life survey
timeFrame: Inclusion and 12-month follow-up
measure: Care received
timeFrame: 12-month follow-up
measure: Personal and family medical history
timeFrame: Inclusion
measure: Sociodemographics
timeFrame: Inclusion
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
state: Loire-Atlantique
city: Brest
country: France
facility: CHRU de Brest
city: Tours
country: France
facility: CHRU de Tours
Study officials:
References: